COMMUNIQUÉS West-GlobeNewswire

OraSure Technologies rejoint la Coalition mondiale contre la drépanocytose afin de favoriser l’accès à un diagnostic plus précoce et aux soins
02/11/2026
Cette collaboration apportera une expertise en matière de diagnostic à une initiative mondiale multipartite axée sur les politiques publiques, le plaidoyer et la mise en œuvre concrète des mesures. BETHLEHEM, [...]
OraSure Technologies Joins the World Coalition on Sickle Cell Disease to Advance Access to Earlier Diagnosis and Care
02/11/2026
Collaboration will bring diagnostics expertise to a global, multi-stakeholder effort focused on policy, advocacy, and practical implementation BETHLEHEM, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc [...]
ICPO ACADEMY FOR THERANOSTICS Launches Advanced Program in Radiomolecular Precision Oncology
02/11/2026
Online curriculum expands with advanced clinical cases in prostate cancer and neuroendocrine tumors including multidisciplinary tumor board illustrations Wiesbaden, November 2, 2026 – Radiomolecular Precision Oncology, [...]
Eton Pharmaceuticals Announces Licensing and Initiation of ET-900 Program Evaluating Mecasermin/IGF-1 for Treatment of Infantile and Epileptic Spasms
02/11/2026
ET-900 targets a potential new indication for mecasermin, the active ingredient in Eton’s INCRELEX ® Eton has licensed patent rights from Baylor College of Medicine covering the use of insulin-like growth factor1 (IGF-1 [...]
Alvotech to Present at Upcoming Investor Conferences in November
02/11/2026
REYKJAVIK, ICELAND (November 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced [...]
Bavarian Nordic Awarded Multi-Year Vaccine Contract by UK Government
02/11/2026
COPENHAGEN, Denmark, November 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has been awarded a new multi-year contract by the UK Government through the UK Health Security Agency (UKHSA) for the [...]
GENFIT présentera ses avancées dans l’ACLF et dans le diagnostic de la MASH lors du congrès AASLD The Liver Meeting® 2026
02/11/2026
ACLF : une stratégie thérapeutique multicibles en développement GENFIT organisera un événement scientifique le 8 novembre 2026 pour présenter sa stratégie dans l’ACLF et le dossier clinique l’ayant conduit à engager [...]
GENFIT to Highlight Progress in ACLF and MASH Diagnostics at AASLD The Liver Meeting® 2026
02/11/2026
ACLF – Advancing a multi-target therapeutic strategy GENFIT to host a scientific event on November 8, 2026 to outline its ACLF strategy and unveil a comprehensive clinical data package supporting the advancement of [...]
Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation
02/11/2026
Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis’ global integrated scientific strategy supporting the advancement of Privosegtor and its expansion into new therapeutic applications Aaron [...]
GUERBET : Update on discussions with financial partners.
02/11/2026
Update on discussions with financial partners Villepinte, November 2, 2026, 8.30 A.m.: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces, further to its [...]
GUERBET : Point d’étape sur les discussions avec les partenaires financiers.
02/11/2026
Point d’étape sur les discussions avec les partenaires financiers Villepinte, le 2 novembre 2026, 8h30 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, [...]
Bavarian Nordic – Completion of Share Buy-Back Program
02/11/2026
COPENHAGEN, Denmark, November 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on September 1, 2026, has now been completed, reaching an aggregate [...]
CROSSJECT annonce la mise à disposition du rapport financier semestriel au 30 juin 2026
02/11/2026
DIJON, France CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique internationale spécialisée dans le développement d'auto-injecteurs sans aiguille pour les situations d'urgence, annonce avoir mis à [...]
CROSSJECT annonce la mise à disposition du rapport financier semestriel au 30 juin 2026
02/11/2026
DIJON, France CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique internationale spécialisée dans le développement d'auto-injecteurs sans aiguille pour les situations d'urgence, annonce avoir mis à [...]
Nouscom Strengthens Leadership and Operational Capabilities, Appointing Loredana Siani, Ph.D., as Chief Technology Officer
02/11/2026
Nouscom Strengthens Leadership and Operational Capabilities, Appointing Loredana Siani, Ph.D., as Chief Technology Officer Promotion follows recent €120 million Series D financing as Nouscom advances NOUS-209 into [...]
Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation
02/11/2026
Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis’ global integrated scientific strategy supporting the advancement of Privosegtor and its expansion into new therapeutic applications Aaron [...]
HUTCHMED Announces Regulatory Filings Accepted for Review for ORPATHYS® plus TAGRISSO® in MET-Driven EGFR-Mutated Lung Cancer in Europe and Japan
02/11/2026
— Follows US FDA new drug application submission in September 2026, marking important global regulatory progress — — Filings supported by positive SAFFRON global Phase III data demonstrating statistically significant [...]
Mesoblast Board Changes
02/11/2026
NEW YORK, Nov. 01, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced rotational changes and retirement of [...]
TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients
01/11/2026
Late-Breaking P4 study, simultaneously published in NEJM, shows CT guidance delivers matched one-year clinical outcomes with shorter procedures, demonstrating pre-procedural CCTA can guide key PCI planning decisions [...]

Pages